Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

gastrointestinal · Mechanism Report

Can donepezil cause gastrointestinal symptoms and weight loss?

Donepezil can cause nausea, decreased appetite, and weight loss; abdominal discomfort is plausible but less directly established.

PlausibleNovember 21, 20269 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Donepezil can cause nausea, abdominal discomfort, decreased appetite, and weight loss through cholinergic gastrointestinal effects.

laying out figure…
3 of 8 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

Donepezil inhibits acetylcholinesterase, increasing cholinergic activity that can affect intestinal movement and gastric secretion. Gastrointestinal symptoms may reduce food intake and contribute to weight loss, with risk influenced by dose and titration speed.

Verified conclusion

Donepezil, an acetylcholinesterase inhibitor used for cognitive symptoms, has a characteristic peripheral cholinergic gastrointestinal adverse-effect profile. The overall claim is supported for nausea, reduced appetite, weight loss, and the cholinergic mechanism; abdominal discomfort is biologically credible but less directly documented for donepezil specifically.

Clinical evidence

  • In pooled placebo-controlled data, nausea occurred in 19% of patients rapidly escalated to 10 mg/day over one week, versus 6% with placebo. With a slower six-week titration, nausea fell to 6%.
  • Decreased appetite, reported as anorexia, occurred in 7% with rapid escalation versus 2% with placebo, and 3% with slower titration.
  • Weight decrease was reported in 3% of donepezil-treated participants versus 1% receiving placebo. At 23 mg/day versus 10 mg/day, reported weight loss was 4.7% versus 2.5%; ≥7% weight loss occurred in 8.4% versus 4.9%, respectively.
  • Abdominal discomfort fits the observed gastrointestinal syndrome, but available evidence does not provide a donepezil-specific incidence estimate for abdominal pain/discomfort.

Mechanistic explanation

  • Donepezil inhibits acetylcholinesterase, increasing and prolonging acetylcholine signaling at peripheral cholinergic receptors. This can stimulate intestinal propulsion and gastric secretion, consistent with nausea, vomiting, diarrhea, abdominal symptoms, and anorexia.
  • Nausea and other gastrointestinal effects can reduce food intake and plausibly contribute to subsequent weight loss, though weight loss does not occur in all patients.

Clinical implications

  • Risk is greatest during initiation and dose escalation. The observed reduction in nausea and anorexia with slower titration supports allowing the recommended 4–6 weeks before increasing from 5 to 10 mg/day.
  • Monitor gastrointestinal symptoms, appetite, dietary intake, and body weight; persistent symptoms or meaningful weight loss warrant clinical review.

Bottom line

  • Donepezil can cause nausea, decreased appetite, and weight loss through cholinergic gastrointestinal effects, with risk influenced by dose and titration speed. Abdominal discomfort is plausible within this syndrome but is less directly established.

References

  1. These highlights do not include all the information needed to use donepezil hydrochloride safely and effectively. See full prescribing information for donepezil hydrochloride tabletsDonepezil Hydrochloride TabletsInitial U.S. Approval: 1996 — dailymed.nlm.nih.gov ↗
  2. Cholinesterase inhibitors for Alzheimer's disease — ncbi.nlm.nih.gov ↗
  3. Weight Loss Associated with Cholinesterase Inhibitors In Patients With Dementia in a National Healthcare System — ncbi.nlm.nih.gov ↗
  4. Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer’s Disease and Parkinson’s Dementia: Systematic Review and Meta-Analysis - Drugs & Aging — link.springer.com ↗
  5. Weight Loss Associated with Cholinesterase Inhibitors in ... — pubmed.ncbi.nlm.nih.gov ↗
  6. Donepezil for mild and moderate Alzheimer's disease — pubmed.ncbi.nlm.nih.gov ↗
  7. The safety and tolerability of donepezil in patients with ... - PMC — pmc.ncbi.nlm.nih.gov ↗
  8. Cholinesterase Inhibitors - StatPearls - NCBI Bookshelf - NIH — ncbi.nlm.nih.gov ↗
  9. Effects of acetylcholinesterase inhibitors on nutritional status in ... — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible6 sourcesCan intermittent tramadol cause nausea and bowel symptoms?→Plausible7 sourcesCan chronic gastrointestinal dysfunction contribute to vitamin D deficiency?→